VBIV: VBI Vaccines, Inc. Company Short-Term Debt

VBI Vaccines Inc. (VBIV) generates revenue by developing treatments for respiratory infections and hepatitis B, relying on stable government contracts. The price visualization on GURU.Markets, where the indicator stands at 0.00, which assists in the asset's base valuation, links this income to strict temperature control during medication transport. However, the business has been weakened by the loss of leading scientists due to a sharp reduction in R&D investment.

This indicator captures the total liabilities of VBI Vaccines Inc. (VBIV) maturing in less than twelve months, allowing for an assessment of liquidity risk and the company's ability to service current loans. By analyzing the short-term debt trend, an investor can determine whether financial resources are sufficient to sustain costly research and development under strict FDA oversight and to protect the patent portfolio.